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100Objectives: To define the durability of aortic valve repair (AVRep) and the effect of surgical timing on late
survival.
Methods: From June 1986 to June 2011, 331 patients underwent elective AVRep for aortic regurgitation
(mean age, 53  17 years; 76% men). The repair methods included commissuroplasty (n ¼ 270; 81%),
triangular resection and plication (n ¼ 106; 32%), resuspension or cusp shortening (n ¼ 102; 31%), and
perforation closure (n ¼ 23; 7%).
Results: In-hospital mortality was 0.6% (2 of 332). Four patients (1%) experienced early repair failure; two
underwent repeat repair. Overall survival was 91% and 81% at 5 and 10 years, respectively. After adjusting
for age, greater left ventricular end-systolic dimension (per 5 mm; hazard ratio [HR], 1.49; 95% confidence
interval [CI], 1.23-1.79; P < .001) and lower ejection fraction (per 5%; HR, 1.42; 95% CI, 1.25-1.63;
P  .001) were significant predictors of long-term mortality. Patients with ejection fraction< 50% and left
ventricular end-systolic dimension> 50 mm had significantly greater odds of late death (HR, 3.46; 95%
CI, 2.05-5.82; P<.001 and HR, 2.08; 95% CI, 1.05-4.12; P ¼ .036, respectively). The risk of aortic valve
reoperation was 10% and 21% at 5 and 10 years, respectively. The presence of severe aortic regurgitation
(HR, 2.2; 95% CI, 1.1-5.06; P ¼ .02) and more than mild regurgitation at discharge (HR, 5.87; 95%
CI, 2.67-12.68; P  .0001) were predictors of late reoperation. Freedom from other valve-related events was
94% and 91% at 5 and 10 years, respectively. Forty-seven patients (21%) with intact valve repair were using
warfarin at the last follow-up visit.
Conclusions: AVRep can be performed with excellent late survival and freedom from valve-related events.
Awaiting the onset of ventricular dysfunction increases the risk of late mortality, warranting earlier consideration
of AVRep for patients with suitable anatomy. (J Thorac Cardiovasc Surg 2014;147:100-8)The preferred surgical intervention and timing of therapy for
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debated.1 Historically, aortic valve replacement (AVR) has
been the default procedure for the surgical management ofe Division of Cardiovascular Surgerya and Department of Biomedical
tics and Informatics,b Mayo Clinic College of Medicine, Rochester, Minn.
ision of Cardiovascular Surgery, Mayo Clinic College of Medicine, funded
esent study, including the statistical analysis.
res: The Division of Cardiovascular Surgery has a research grant titled
domized biological aortic valve replacement’’ funded equally by Edwards
ciences, St Jude Medical, and the Sorin Group. Dr Suri is the Principal
tigator for the PERCEVAL Investigational Device Exemption trial funded
Sorin Group. Dr Park has served on the advisory board of Thoratec and as the
e director for a Cleveland Clinic conference. None of the disclosures pertain
current investigation. All other authors have nothing to disclose with regard
mercial support.
the 93rd Annual Meeting of The American Association for Thoracic
ry, Minneapolis, Minnesota, May 4-8, 2013.
d for publication May 5, 2013; revisions received July 15, 2013; accepted for
ation Aug 1, 2013; available ahead of print Sept 30, 2013.
for reprints: Rakesh M. Suri, MD, DPhil, Division of Cardiovascular
ry, Mayo Clinic College of Medicine, 200 First St SW, Rochester,
5905 (E-mail: suri.rakesh@mayo.edu).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.08.015
The Journal of Thoracic and Cardiovascular Surgaortic valve disease, with repair techniques heterogeneously
and infrequently used in those with isolated AR.2,3 During
the past decade, experience with aortic valve repair
(AVRep) has expanded, driven in part by improvements in
the echocardiographic delineation of cusp anatomy, the
quantification of anatomic abnormalities, and consequent
to an increasing facility with valve-sparing root replacement
among cardiac surgeons. The impetus to develop and
propagate valvuloplasty strategies for isolated AR in the
absence of calcific stenosis was founded on the belief that
AVRep would offer significant advantages to patients in a
manner analogous to mitral valve repair by avoiding
prosthesis-related complications such as mismatch, endo-
carditis, thromboembolism, and early device senescence.4
An improved understanding of normal aortic root geometry
and critical elements of functional aortic cusp coaptation has
also facilitated the evolution of AVRep, in particular, for
those with isolated valve abnormalities in the absence of
aortic root dilation.5
Despite an increasing familiarity with AVRep techniques
and the availability of retrospective outcome data,6-8 the
predictors of survival and reoperation risk after isolated
AVRep remain unclear, particularly in relation to theery c January 2014
Abbreviations and Acronyms
AR ¼ aortic regurgitation
AVR ¼ aortic valve replacement
AVRep ¼ aortic valve repair
CI ¼ confidence interval
EF ¼ ejection fraction
HR ¼ hazard ratio
LVESD ¼ left ventricular end-systolic dimension
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Deffect of surgical timing. We thus sought to explore the
long-term outcomes of isolated AVRep in the absence of
aortic root dilation or dissection and, also, to test the
hypothesis that the timing of repair for isolated AR might
affect long-term survival postoperatively.
METHODS
After institutional review board approval, we identified consecutive
patients who had undergone AVRep for significant AR from June 1986 to
June 2011 in theMayoClinic Adult Cardiac Surgical Database. All patients
provided written informed consent for the study. We excluded those with
AR associated with acute or chronic aortic dissection or ventricular septal
defect and patients with aortic root dilation andmoderate to severe ARwho
had undergone aortic valve-sparing aortic sinus wall replacement (n¼ 113)
to specifically address the subset of patients with significant AR related to
the aortic valve cusps or annulus (n ¼ 331). A retrospective review of the
medical records was performed.
All patients underwent surgical treatment of the aortic valve according
to current North American guidelines, with either the presence of
symptoms or left ventricular dysfunction.1 Of the patients, 196 (59%)
had severe AR preoperatively. Other indications included the existence
of subsevere AR in patients undergoing concomitant surgery for severe
mitral regurgitation or coronary artery revascularization. Intraoperative
transesophageal echocardiography was routinely used, focusing on the
cusp anatomy, mechanism of AR, and AR jet (eccentric or central) and
to judge the adequacy of valve repair. All patients also underwent repeat
echocardiography at discharge from the hospital.
The patients were categorized into 4 groups: group 1, annular dilation
without cusp prolapse (n ¼ 77; 23%); group 2, bicuspid aortic valve
(n ¼ 133; 41%), further divided into those with (n ¼ 99) and without
(n ¼ 34) a thickened raphe; group 3, tricuspid aortic valve with cusp
prolapse (n ¼ 96, 29%); and group 4, cusp perforation (n ¼ 23; 6%).
Two patients underwent minor shaving and/or debridement of a cusp
because of restricted valve mobility.
Operative Techniques
Identification of cusp prolapse or restriction was facilitated by
examining the cusp motion and comparing the position of the free margin
to a reference coaptation point at the height of the free margin of the normal
cusp.9 If 2 cusps were prolapsing, the nonprolapsing cusp was used as the
reference. Rarely, if all 3 cusps had prolapsed, we attempted to restore
coaptation to well above the annular plane at the mid-sinus level. Excess
motion and an elongated free margin length were also frequently observed.
Restriction was recognized by the presence of reduced cusp motion. All
procedures were performed through a full or minimedian sternotomy
with cardiopulmonary bypass and central cannulation. Repair for annular
dilation was accomplished by subcommissural annuloplasty (or ‘‘commis-
suroplasty’’). It was performed by placement of pledgeted, horizontal
mattress stitches with 3-0 or 4-0 braided polyester suture through the aortic
wall at each commissure to narrow the angle of the subcommissuralThe Journal of Thoracic and Catriangles, thereby reducing the circumference of the annulus and increasing
the surface area of cuspal coaptation (Figure 1, A).10 In most patients with
bicuspid aortic valve disease, regurgitation was caused by retraction and/or
prolapse of the conjoint cusp. The most frequent anatomic finding was a
conjoint cusp beneath the right and left coronary sinuses. Such bicuspid
valves were repaired using limited triangular resection and suture
reconstruction of the median raphe with 5-0 or 6-0 polypropylene suture
(Figure 1, B). This maneuver shortened and elevated the free edge of the
cusp, increasing the area of coaptation and permitting apposition with
the noncoronary cusp. In a few patients with pliable and nonrestricted
cusps, prolapse of the conjoint or the noncoronary cusp was corrected using
simple mid-cuspal plication sutures without resection (Figure 1, B).
Subcommissural annuloplasty was combined with cusp repair when
indicated. Regurgitation of the tricuspid aortic valves because of prolapse
of1 cusps was frequently treated using cusp plication, either centrally or
near the commissure with 5-0 polypropylene suture,11 or resuspension of
the free edge of the cusp by weaving a 5-0 polytetrafluoroethylene suture
along the free edge and anchoring it through the aortic wall (Figure 1 C).
Cusp perforation resulting from infective endocarditis or iatrogenic injury
was repaired by patch closure using pericardium secured with interrupted
or continuous 6-0 polypropylene suture (Figure 1, D).
Follow-up
Clinical follow-up was conducted through outpatient visits or by mailed
questionnaire. Information on survival status, valve-related complications,
including thromboembolism and endocarditis, and reoperation were
obtained from the clinical records, by telephone interviews, and from
the Social Security Death Index. Transthoracic echocardiography was
obtained in 89% of the surviving patients. The mean follow-up duration
was 5.75  4.75 years and was available for 302 of the 328 hospital
survivors (92%).
Statistical Analysis
Descriptive statistics for categorical variables are reported as fre-
quencies and percentages and continuous variables as the mean standard
deviation or median and range, as appropriate. Kaplan-Meier analyses were
used to create survival curves and calculate the 5-, 10-, and 15-year survival
and freedom from reoperation statistics. Cox regression models were used
to determine univariate and/or multivariate predictors of late mortality and
reoperation. The multivariate model considered the univariate significant
variables (P < .05), with model selection using the stepwise method
(backward and forward methods resulted in the same model). Late survival
was compared using an age- and gender-matched general population using
the 1-sample log-rank test. All statistical tests were 2-sided, with the a level
set at 0.05 for statistical significance.RESULTS
In-Hospital Outcomes
The mean age was 53  17 years (median, 54; range,
15-89). Of the 331 patients, 254 were men (76%) and 77
were women (24%). The most common presenting
symptoms were fatigue, palpitations, and shortness of
breath. A total of 103 patients (31%) had New York Heart
Association class III-IV symptoms preoperatively. Patients
with bicuspid valves were younger and had fewer coexisting
medical conditions than those with tricuspid aortic valve
anatomy (Table 1). The mean crossclamp and cardiopulmo-
nary time was 32  17 minutes and 44  21 minutes for
isolated AVRep, respectively. Concomitant procedures
were performed in 180 patients (54%). The most commonrdiovascular Surgery c Volume 147, Number 1 101
FIGURE 1. Aortic valve repair techniques. A, Annular dilation of aortic valve causing central regurgitation. Plication stitches are placed in the aortic wall
at each commissure. B, Bicuspid aortic valve. Triangular resection of the conjoint cusp raphe is performed and then reconstructed using monofilament
suture, with mid-cusp plication of prolapsing bicuspid aortic valve cusp without raphe. C, Tricuspid valve with prolapse. Central plication or Trusler stitch
or free edge resuspension can be used. D, Patch repair of perforation.
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36%), coronary artery bypass grafting (n ¼ 47, 26%),
and replacement of the dilated tubular portion of the
ascending aorta (n ¼ 38, 21%; Table 2).
A second cardiopulmonary bypass run was necessary in
11 patients (3%) to correct residual AR. Two early deaths
(0.6%) occurred: an 80-year-old man, who had undergone
aortic and mitral valve repair, coronary artery bypass
grafting, and extended left ventricular septal myectomy,
and a 76-year-old woman, who had undergone aortic
and tricuspid valve repair with mitral valve replacement.
No deaths occurred in the bicuspid AVRep subgroup.
Four patients (1%) underwent aortic valve reoperation
during the index admission. In each patient, the routine
predischarge echocardiogram identified significant ARTABLE 1. Patient demographics
Preoperative characteristics Total (n ¼ 331)
Age (y) 53  17
Male gender 251 (76)
NYHA class III-IV 103 (31)
Smoking 81 (24)
Hypertension 136 (41)
Diabetes mellitus 29 (9)
Connective tissue disorders 11 (3)
Previous MI 21 (6)
Previous cardiac surgery 13 (4)
Atrial fibrillation 64 (19)
LVEF (%) 59  8
Preoperative severe AR 196 (59)
LVESD (mm) 39  8
LVEDD (mm) 59  9
Associated major cardiac procedures 258
Data presented as mean  standard deviation or n (%). NS, Not significant; NYHA, New
fraction; AR, aortic regurgitation; LVESD, left ventricular end-systolic dimension; LVEDD
102 The Journal of Thoracic and Cardiovascular Surgcompared with the intraoperative echocardiogram. All
4 patients had dehiscence of the plication sutures noted.
Repeat repair by plication was possible in 2 patients,
and 2 patients required valve replacement because the
remaining tissue quality was suboptimal.
Late Survival
There were 58 late deaths. Of these, 17 (29%) were
cardiovascular related and 16 (28%) were not; in 25 patients
(43%), the cause of death was unknown. Overall, late
survival at 5, 10, and 15 years was 91%, 80%, and 58%,
respectively, and was statistically indistinguishable from a
comparable age- and gender-matched population (P ¼ .52;
Figure 2, A). The corresponding estimated freedom from
known cardiac-related death was 98%, 95%, and 91%.Tricuspid (n ¼ 198) Bicuspid (n ¼ 133) P value
61  15 42  14 <.001
138 (70) 116 (87) NS
81 (39) 22 (17) <.001
48 (24) 33 (26) NS
98 (48) 38 (30) <.001
20 (10) 9 (8) NS
10 (5) 1 (0.7) <.01
20 (9) 1 (0.7) <.001
12 (6) 1 (0.7) <.001
52 (26) 12 (9) <.001
59  7 61  9 NS
97 (49) 99 (74) <.001
38  8 39  8 .014
58  9 60  9 .001
132 (66) 41 (30) <.001
York Heart Association; MI, myocardial infarction; LVEF, left ventricular ejection
, left ventricular end-diastolic dimension.
ery c January 2014
TABLE 2. Intraoperative and postoperative data
Variable Value
Cardiopulmonary bypass time (min)
Total (n ¼ 331) 60  30
Isolated AVRep (n ¼ 123) 46  21
Crossclamp time (min)
Total (n ¼ 331) 44  21
Isolated AVRep (n ¼ 123) 32  17
Major associated procedures 180 (78)
Mitral valve repair 60
Mitral replacement 6
Coronary artery bypass grafting 47
Ascending aorta replacement 38
Septal myectomy 13
TV procedure 8
Other 8
Operative techniques
Commissural plication 270 (81)
Partial cusp resection with plication 106 (32)
Resuspension or cusp shortening 102 (31)
Cusp perforation closure 23 (7)
Cusp shaving 35 (10)
Early AV reintervention 4 (1)
Repeat repair 2 (0.5)
Replacement 2 (0.5)
Postoperative outcomes
Early death 2 (0.5)
Bleeding 8 (2.4)
CVA 6 (1.8)
Prolonged ventilation 9 (2.6)
Data presented as mean standard deviation or n (%). TV, Tricuspid valve; AV, aortic
valve; CVA, cerebrovascular accident; AVRep, aortic valve repair.
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mortality. Univariate analysis demonstrated the following
preoperative variables as significant predictors: New
York Heart Association class III-IV symptoms (hazard
ratio [HR], 1.88; 95% confidence interval [CI],
1.12-3.17; P ¼ .02), larger left ventricular end-systolic
dimension (LVESD; per 5 mm; HR, 1.51; 95% CI,
1.25-1.82; P  .001), poorer left ventricular ejection
fraction (EF; per 5%; HR, 1.42; 1.25-1.63; P  .001),
older age (HR, 1.06; 95% CI, 1.04-1.08; P ¼ .001),
and nonbicuspid aortic valve anatomy (HR, 5.0; 95%
CI, 2.08-11.0; P ¼ .001). To determine which of these
factors independently influenced late mortality, multi-
variate analysis was performed. The overall model
revealed that larger LVESD (per 5 mm; HR, 1.49; 95%
CI, 1.23-1.79; P< .001) and older age (HR, 1.06; 95%
CI, 1.04-1.08; P ¼ .001) were independently associated
with diminished late survival (Table 3). Additional
exploratory modeling revealed that LVESD and EF
correlated negatively (r ¼ 0.6; P < .001); hence,
when LVESD was removed from the model, a decreased
preoperative EF (per 5%; HR, 0.76; 95% CI, 0.66-0.87;
P < .001) was a significant predictor of improved lateThe Journal of Thoracic and Casurvival, along with older age. The risk of late death
was 3.5-fold greater in those with a preoperative EF
of <50% (HR, 3.46; 95% CI, 2.05-5.82; P < .001;
Figure 2, B) and 2-fold greater in patients with a preope-
rative LVESD> 50 mm (HR, 2.08; 95% CI, 1.05-4.12;
P ¼ .04; Figure 2, C). Also, the survival of patients
with EF< 50% and LVESD> 50 mm was significantly
worse than that in the age- and gender-matched controls
(P ¼ .004 and P ¼ .005, respectively).
A subgroup analysis of patients with severe AR pre-
operatively as the predominant cause for cardiac operation,
who did not require other major associated cardiac surgical
procedures, revealed survival of 92% and 85% at 5 and
10 years, respectively. A poorer preoperative EF (per 5%;
HR, 0.62; 95% CI, 0.48-0.81; P<.001) and larger LVESD
(per 5 mm; HR, 2.65; 95% CI, 1.62-4.3; P  .001) were,
again, both significant predictors of late mortality after
adjustment for age.
Late Reoperation
Of the 331 patients, 44 (13%) required AVR during the
follow-up period. However, the primary indication for late
reoperation was severe AR and/or stenosis in only 40
patients (12%; group 1, n ¼ 10; group 2, n ¼ 13; group
3, n ¼ 16; and group 4, n ¼ 1). No difference was found
in the need for late aortic valve reoperation among the 4
anatomic groups (P ¼ .66). The most common causes of
recurrent AR identified at reoperation were scarring and
calcification of the aortic valve (n ¼ 17), recurrent dilation
and central regurgitation (n ¼ 13), recurrent prolapse
(n ¼ 4), perforation at the repair site (n ¼ 3), and unknown
(n ¼ 3). The median interval between the initial operation
and late aortic valve reoperation was 3.9 years (range, 9
months to 15.6 years) overall. Freedom from late aortic
valve reoperation was 90%, 79%, and 72% at 5, 10, and
15 years, respectively (Figure 2, D). The presence of severe
preoperative AR (HR, 1.99; 95% CI, 1.03-3.85; P ¼ .04)
and more than mild AR at discharge (HR, 5.87; 95% CI,
2.67-12.68; P  .0001) were significant predictors of late
reoperation.
In a subgroup analysis of patients with severe AR, 30
patients (15%) needed AVR (group 1, n ¼ 6, 21%; group
2, n ¼ 12, 11%; group 3, n ¼ 11, 23%; group 4, n ¼ 1,
7%). Freedom from late aortic valve reoperation was
88%, 74%, and 67% in the severe AR group at 5, 10,
and 15 years, respectively.
Echocardiographic Follow-up
Follow-up echocardiograms were available for 205
patients with intact valve repair (89% of the surviving
patients) and revealed freedom from late AR grade>2þ
of 88%, 75%, and 58% (Figure 2, E) in the overall group
and 86%, 71%, and 54% in patients with severe AR at 5,
10, and 15 years, respectively.rdiovascular Surgery c Volume 147, Number 1 103
FIGURE 2. A, Kaplan-Meier curve detailing late survival compared with healthy age- and gender-matched US population. B, Kaplan-Meier curves for
survival for patients with ejection fraction (EF)<50% and>50%. C, Kaplan-Meier curves for survival for patients with left ventricular end-systolic
dimension (LVESD)<50 and>50 mm. D, Kaplan-Meier curve for freedom from late aortic valve (AV) reoperation (re-op). E, Kaplan-Meier curve for
freedom from aortic regurgitation (AR) grade>2þ.
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Of the 271 late survivors, 71 (26%) were receiving
warfarin prophylaxis for various reasons, including atrial
fibrillation in 37, mechanical aortic or mitral prosthesis in
24, a history of stroke in 7, or deep vein thrombosis in 3.
In contrast, only 47 (21%) of the patients with intact AVRep
required warfarin at the last follow-up examination. During
the follow-up period, 10 embolic events (2 transient
ischemic attacks and 8 strokes) and 10 gastrointestinal
bleeding events (all patients receiving warfarin) occurred.
One patient developed endocarditis, which was medically
managed. Freedom from valve-related events (ie, stroke,TABLE 3. Univariate and multivariate predictors of late mortality
Variable
Univariate predictors
HR (95% CI)
Age 1.06 (1.04-1.08)
Bicuspid valve 0.20 (0.09-0.48)
NYHA class III-IV 1.88 (1.12-3.17)
EF (5% increase) 0.7 (0.61-0.81)
LVESD (5-mm increase) 1.15 (1.09-1.22)
EF<50% 3.46 (2.05-5.82)
LVESD>50 mm 2.08 (1.05-4.12)
HR, Hazard ratio; CI, confidence interval; NYHA, New York Heart Association; EF, eject
104 The Journal of Thoracic and Cardiovascular Surgbleeding, and endocarditis) was 95%, 92%, and 87%
and 97%, 95%, and 91% for the isolated AVRep group at
5, 10, and 15 years, respectively. The anatomic group-
stratified incidence of valve-related events is listed in
Table 4.
DISCUSSION
During the past 20 years, marked progress has been made
in the understanding of the functional anatomy of the aortic
valve, including a greater appreciation of the interrelation-
ship between the aortic cusps and sinuses of Valsalva.5,7,12
Although an increasing body of evidence supports theMultivariate predictors
P value HR (95% CI) P value
<.001 1.06 (1.04-1.08) <.001
<.001
<.001
<.001 0.76 (0.66-0.87)* <.001
<.001 1.49 (1.23-1.79) <.001
<.001
.036
ion fraction; LVESD, left ventricular end-systolic dimension. *Excluding LVESD.
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TABLE 4. Valve-related events (group-wise distribution)
Variable
Group 1
(annular dilation; n ¼ 77)
Group 2
(bicuspid; n ¼ 133)
Group 3
(tricuspid prolapse; n ¼ 96)
Group 4
(perforation; n ¼ 23)
Reoperation
Total (n ¼ 40)* 10/77 (13) 12/133 (9) 17/96 (18) 1/23 (4)
Severe AR group (n ¼ 30)* 6/28 (21) 12/107 (11) 11/47 (34) 1/14 (7)
Interval to reoperation (y)
Mean  SD 4.2  4 6.5  4.5 5.8  4 4.99
Median (IQ, 25%-75%) 2.6 (1-7) 7.7 (1.3-9.7) 5.3 (2.6-8)
AR>2þ (n ¼ 50)* 13/77 (17) 13/133 (10) 23/96 (24) 1/23 (4)
AR>2þ (severe AR group; n ¼ 36)* 6/28 (21) 13/107 (12) 16/47 (34) 1/14 (7)
Death (n ¼ 58)y 23/77 (28) 6/133 (5) 25/66 (26) 4/23 (17)
Valve-related events (n ¼ 21)* 7/77 (9) 5/133 (4) 9/96 (9) 0
Warfarin (n ¼ 71) 23/77 (30) 21/133 (16) 23/96 (24) 4/23 (17)
Data in parentheses are percentages. AR, Aortic regurgitation; SD, standard deviation; IQ, interquartile range. *P>.05. yP<.05 for group 2 versus rest of groups.
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late outcome of isolated cup repair for severe AR has been
less well described. Our large series of isolated AVRep has
detailed the safety of this operation, with very low overall
early mortality (0.6%), particularly for bicuspid aortic
valve disease (0%). The long-term outcomes of AVRep
were also excellent, with normalization of late survival to
that of an age- and gender-matched population, along
with rates of freedom from aortic valve-related events and
reoperation comparable to those for biologic aortic
valve substitutes. Importantly, patients who undergo
AVRep before the onset of left ventricular dilation
(LVESD< 50 mm) or dysfunction (EF> 50%) benefited
from preservation of late survival. These data call for an
earlier recognition of significant AR to facilitate prompt
referral for surgical intervention in those with cusp anatomy
suitable for valve repair.
The mean age of our present study cohort was 53
years (42 years for those with bicuspid disease).
Thus, durability must be considered with reference to
the early senescence of biologic AVR in young
patients13,14 in contrast to the greater durability of
biologic AVR in older populations.15,16 Our previous
report comparing bicuspid AVRep versus bioprosthetic
replacement revealed no significant differences in
survival or reoperation at a mean follow-up of 5.1 years
(P < .12).17 Smedira and colleagues13 found that the
instantaneous risk of explantation ‘‘accelerated exponen-
tially’’ from 12 (13%) to 19 years (53%) after pericardial
AVR in nonelderly patients. Chan and associates18
reported that the median interval to reoperation in patients
undergoing AVR with the current generation stented aortic
bioprostheses was 7.7 years in patients <40 years. The
present results of AVRep compared favorably, suggesting
that repair is an acceptable alternative to biologic aortic
valve substitutes in the current era, although a limiting
factor might have been that both the clinical and echo-
cardiographic follow-up was 89% complete.The Journal of Thoracic and CaThe reoperation rates after AVRep have been steadily
declining because of the enhanced understanding of
aortic valve physiology, predictors of repair failure
(coaptation level, cusp height, and coaptation length), and
standardization of repair techniques with the availability
of classification schemes. Despite this progress, the
practices of aortic and mitral valve repair differ in several
important ways. First, the techniques of AVRep have varied
among centers.2 Second, tissue quality is critical to the
technical feasibility and durability of AVRep but is less
frequently a concern in those with degenerative mitral
disease. The presence of severe AR was a significant
predictor for late aortic valve reoperation in the present
series, which could suggest that pronounced cusp stretching
might have led to some degree of tissue weakening. Third,
the frequency of congenital bicuspid variations, particularly
in young patients, might limit the routine application of
standard repair techniques, thus influencing the frequency
of AVRep. Finally, although it is rare to encounter deficient
mitral valve leaflet tissue in the setting of degenerative
mitral regurgitation, the same is not true of degenerative
AR. The relative paucity of cusp surfaces available
for reconstruction can, at times, preclude repair, particularly
in the presence of cusp restriction, thickening, or
fenestration.
The durability of AVRep was statistically similar among
the 4 anatomic groups in our analysis, just as was the late
recurrence of AR and the need for aortic valve reoperation.
The homogeneity of durability outcomes was likely
attributable to application of the lessons learned with AVRep
during the past 20 years at our center, including the system-
atic assessment of aortic valve pathologic features and
valve-specific tailoring of the repair strategy. Most of the
early data on bicuspid valve repair detailed a 10-year
reoperation rate of approximately 20%, primarily
because of recurrent AR.19 Two recent reports by Aicher
and colleagues20 and de Kerchove and colleagues21 have
asserted that improvements in the durability of bicuspidrdiovascular Surgery c Volume 147, Number 1 105
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annular reduction maneuvers. Although, we have not
introduced these into our practice, we remain interested as
long-term results emerge.
We propose that several patient subsets might benefit
from enhanced efforts to offer AVRep. Despite the similar
statistical durability of AVRep among the 4 anatomic
subgroups, our data can be interpreted as supportive of
AVRep for young patients with bicuspid AR, who had had
numerically fewer reoperations and longer median interval
to repair failure. Only 21% of AVRep patients with intact
AVRep required warfarin (6% with bicuspid repair alone),
an appealing lifestyle-related benefit in those who are
young, active, and of childbearing age. Second, nonelderly
patients with tricuspid prolapse or aortic annular dilation
could also benefit from AVRep instead of AVR, particularly
those undergoing concomitant cardiac surgical procedures.
Third, the presence of isolated cusp perforation related to
healed endocarditis or iatrogenic injury might be associated
with greater reproducibility of repair with numerically
fewer reoperations, perhaps because a single element of
the valvular–aortic complex was perturbed. In contrast,
elderly patients with nonbicuspid- and nonperforation-
related AR might be less likely to realize a significant
survival or durability-related benefit from AVRep compared
with bioprosthetic replacement.
The current consensus statements have recommended
AVR for asymptomatic patients with AR when the EF is
<50% and/or the LVESD is>55 mm.1 Unlike the trend
toward early surgery for asymptomatic, severe degenerative
MR, a greater threshold exists before surgery will be
recommended to treat severe AR, perhaps because these
patients have historically required AVR. Additionally,
young patients with AR often remain asymptomatic
for many years, with normal left ventricular systolic
function because of compensatory mechanisms.1 Concern-
ing, however, is that the progression to asymptomatic left
ventricular dysfunction is approximately 1.2% annually
in patients with severe AR1; thus, by the time symptoms
have developed, myocardial impairment might have
increased the perioperative risk, including postoperative
heart failure and death.22 Our presented data indicate that
AVRep is capable of restoring late patient survival to that
of an age- and gender-matched population, supporting the
assertion that early correction of severe AR before the onset
of severe left ventricular dysfunction (LVESD>50 mm or
EF<50%) is prudent. Similar findings were obtained in our
previous study of patients with AR undergoing AVR,23 in
whom larger indexed left ventricular systolic and diastolic
dimensions were both associated with increased late
mortality. Newer methods to assess myocardial function
using cardiac magnetic resonance imaging, tissue Doppler
imaging, or speckle tracking might play a future role in
the decisions regarding the timing or AVRep
24; however,106 The Journal of Thoracic and Cardiovascular Surgthe present data support a more aggressive stance in ad-
dressing chronic AR in those who are candidates for AVRep.Study Limitations
The present study was a retrospective analysis spanning
almost 20 years, during which, our techniques, approach,
and intent to perform AVRep have evolved. Although not
the purpose of the present report, a future prospective trial
comparing AVRep and AVR in risk-matched young
patients (age< 60 years) would convey additional useful
information capable of informing the decision to offer
AVRep versus AVR. The exclusion of patients with aortic
sinus and/or root pathologic features or those otherwise
undergoing aortic root surgery could be challenged by those
who believe that annular stabilization maneuvers performed
during aortic valve reimplantation are important. However,
aortic valve reimplantation for AR in the absence of aortic
root dilation has not been routinely used at Mayo Clinic to
date.CONCLUSIONS
AVRep for significant AR can be performed with near 0%
early mortality, normalizing late survival and offering
good durability. The low incidence of valve-related compli-
cations and infrequent requirement for anticoagulation
make AVRep an attractive option, particularly for young
patients with thin, pliable, andmobile aortic cusps and those
with bicuspid configuration. Early referral for AVRep for
patients with suitable anatomy should be performed
before the onset of left ventricular dilation or dysfunction
to optimize long-term survival.
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Dr Hans-Joachim Sch€afers (Homburg/Saar, Germany). I
congratulate Dr Suri and his colleagues for the excellent results
and the excellent presentation. They have shown that AVRep can
be performed with low morbidity and mortality and very good
stability, which, at least in the pathologic entities shown here,
exceeds the mean durability of a biologic AVR for the age group.The Journal of Thoracic and CaThey have identified pathologic entities that seem to benefit more,
and, most importantly, they bring up the point of whether we
should wait with an operation until LV dysfunction sets in or
rather propose surgery before the onset of LV dysfunction.
I have 2 comments and 2 questions.
In our experience, the stability of a repaired tricuspid valve
significantly exceeds that of a bicuspid valve. You showed
different results, although the difference was not statistically
significant. Could you elaborate on the reasons for the slightly
higher risk of reoperation in tricuspid valves? Was this related to
the technique of cusp repair, the technique of annular stabilization,
or does it rather reflect the more difficult learning curve of
assessing valve configuration in tricuspid aortic valves?
Dr Suri. Thank you, Professor Sch€afers, for those questions.
This is a curious finding and, as you point out, although we did
not demonstrate a statistically significant difference in reoperation
rates among the pathologic-anatomic subgroups, we will continue
to analyze these data as the available follow-up duration lengthens
and the total number of repairs available for analysis increases.
As you know, patients with tricuspid aortic valve prolapse often
present at an older age than those with bicuspid regurgitation, and,
therefore, we hypothesized that due to the, at times, sclerotic
nature of the aortic cusps in the older patients with poor tissue
quality, this might have been responsible for the slightly increased
raw number of recurrences. That said, with the new echocardio-
graphic tools available, including measurement of both the
annulus and the coaptation margins, as you have championed,
we hope to further elucidate the predictors of reoperation with
greater precision in the future.
Dr Sch€afers. You proposed earlier surgery, and one could go as
far as proposing surgery for AR similar to that for mitral
regurgitation, that is, every severe mitral regurgitation should be
repaired. However, we need to remember that this is primarily
recommended for mitral pathologic entities, which can be repaired
with a likelihood of 90%.
To translate such a concept into the treatment of AR, of course,
we need to consider the total number of patients with ARwho go to
the operating room. In other words, we need to define the
denominator. This, of course, is difficult in such a retrospective
study. Nevertheless, can you explain or comment on the reasons
for exclusion from AVRep and rather the decision for primary
AVR?
Dr Suri. The questions are good ones—(1) will AVRep
ever have a 99% success rate, such as mitral valve repair for
degenerative leaflet prolapse does in the current era; and (2) will
early AVRep ever be enthusiastically endorsed at the guideline
level? Several differences between degenerative aortic and mitral
disease must be considered when we address these questions.
The first 2 differences are technical ones: the first being the relative
lack of aortic cusp tissue available, and the second, the rather
greater unpredictability of cusp tissue quality compared with
that of mitral valve leaflets. We also must acknowledge disparities
in knowledge—even if aortic repair were to become more
widely available, the heterogeneous historic echocardiographic
quantification of aortic valve regurgitation has led to a lag in our
understanding of the effect of uncorrected severe AR on long-
term survival. It will thus take some time for correction of AR
with aortic repair to become widely recognized as an operationrdiovascular Surgery c Volume 147, Number 1 107
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that were to occur, however, the outcomes might remain less
uniform than the enviable results we have seen for degenerative
mitral valve disease owing to the important differences in tissue
characteristics I mentioned earlier.
Thus, if we had to put things together in moving AVRep
forward, our perspective would be as follows. Number 1, as you
point out, we need to understand the denominator; in other words,
which patients truly have severe aortic insufficiency that is
repairable? Number 2, can we more accurately describe, as you
and Professor El-Khoury, Dr David, and others in the room have
done, the pathoanatomic subgroups we are speaking about to better
communicate among centers? Accomplishing these aims will
better allow us to standardize repair maneuvers and relate them
to the mid- and late-term outcomes. The establishment of
international multicenter registries will facilitate a better
understanding of how the timing of surgery and surgery type
(repair vs replacement) relate to long-term survival, heart failure,
and reoperation risks. Ultimately, consensus statements might
recommend that AVRep be performed before prognosis-limiting
events such as LV dilation or dysfunction, analogous to those
relating to mitral valve repair currently. Once again, important in
all this is developing good judgment in determining who should
undergo AVRep and which patients might be best served by AVR.
Dr Sch€afers.What were the exclusion criteria for repair? What
made you shy away from repair that you found on the intraopera-
tive transesophageal echocardiography or inspection?
Dr Suri. We would tend favor AVR for patients with calcified
cusps that are immobile or retracted or those with poor tissue
quality, particularly, if they are elderly.
Dr Sch€afers. Thank you. My congratulations for this important
study, and I would like to thank the Society for the privilege of
discussing it.
Dr Suri. Thank you, Professor Sch€afers.
Dr Khalid Rasheed (Karachi, Pakistan). Congratulations for
this excellent presentation, but as has been said, there is always
room for improvement. It has been recognized that in AVRep or
reconstruction the sinotubular junction also has a vital role. In
your repair techniques, do you do anything to either stabilize or
fix the sinotubular junction so that it does not dilate and lead to
valve failure?
Dr Suri. Thank you for the question. I would like to acknow-
ledge our former fellow and now surgical associate, Dr Vikas108 The Journal of Thoracic and Cardiovascular SurgSharma, for diligently combing through these records. In
doing so, we have removed all cases of aortic aneurysm
pathology from the present analysis, except for those with solely
supra-sinotubular junction dilatation, to focus on the performance
of AVRep itself. In general, outside of the present series, if the
sinotubular junction is dilated, we do downsize it, using an
appropriately sized graft. We do not, however, fix the sinotubular
junction routinely to a specific dimension and have not noted
progressive sinotubular junction dilatation to be the mechanism
of repair failure in our experience. Logically, if sinotubular
dilatation occurs in conjunction with annular dilatation, we would
address the annulus and also downsize the sinotubular junction in
the same operation.
Dr Joseph Ladowski (Ft Wayne, Ind). I would like to point out
a fairly minor error in your abstract, which raises a more important
question, and that is, you state that of the 227 patients available for
follow-up, only 47 were taking warfarin and state that that was
16%. It is actually>20%. That, combined with your reoperation
rate of>20% at 10 years, leads me to ask, you very elegantly
told us which patients you would not repair going into this, but
now that you have all this experience, which ones do you wish
you had not repaired?
Dr Suri. I think the interpretation might need a little
clarification. We actually were speaking about those who
underwent AVRep for primary AR not requiring concomitant
nonaortic valve operations. Thus, excluding those who had, for
instance, undergone replacement of their tricuspid valve or
mitral valve with a mechanical prosthesis, necessitating warfarin
anticoagulation, only roughly 20% of the remaining population
was using oral anticoagulation at the last follow-up visit.
The second point is in whom we would consider repair. I think I
alluded to that in my previous response, but I will reiterate for
clarity. Dr Schaff has performed the greatest number of repairs
in the present report. In general, surgeons at Mayo Clinic consider
aortic replacement for severe aortic insufficiency in elderly
patients and those with diminished cusp mobility, poor tissue
quality, or cusp calcification. However, as we have demonstrated
in the presentation, the exponential failure rate of bioprosthetic
valves in younger patients deserves consideration. AVR in those
with a pliable, mobile aortic valve might no longer be the default
procedure in the current surgical era, especially for young patients,
because experience with AVRep is growing and the overall
durability has been demonstrated.ery c January 2014
